Jump to content
World's Largest Herpes Support Group
Sign in to follow this  
RNY18

CRISPR-CAS 9 New Target Variants

Recommended Posts

oneday

For anyone who can't read it:

 

New CRISPR-Cas9 Variants Improve Targeting Ability of Base Editors

May 20, 2019
 
| 
crispr_1.jpg?itok=C9Sr6-Kf

NEW YORK (GenomeWeb) – A team led by researchers at the Broad Institute and the University of California, Berkeley has engineered new CRISPR-Cas9 variants that widen the targeting scope of base editors, thus broadening the number of human pathogenic variants that could potentially targeted.

"Indeed, an analysis of human pathogenic single nucleotide polymorphisms in ClinVar reflects a substantial improvement in the fraction of targetable SNPs when considering the expanded [cytosine or adenine base editors'] editing windows compared with their unpermuted counterparts," the authors wrote in their study in Nature Biotechnologytoday

 
 
 

For base editing to successfully occur, the target sequence must be near a protospacer adjacent motif (PAM) that is recognized by the Cas9 domain, and the target nucleotide must be located within the editing window of the base editor. To increase the targeting scope of base editors, the researchers engineered six optimized variants of the adenine base editor (ABE) ABEmax, which use Streptococcus pyogenes Cas9 (SpCas9) variants compatible with non-NGG PAMs.

They also used circularly permuted Cas9 variants (CP-Cas9) to produce four cytosine base editors (CBEs) and four ABEs with an editing window of up to about eight to nine nucleotides, compared to their original editing window of about four to five nucleotides.

"The resulting CP-CBEmax variants exhibit higher product purities, in addition to expanded editing windows, while CP-ABEmax variants maintain the high product purities typical of ABEs," the authors wrote. "These CBE and ABE variants expand the targeting scope of base editing."

The researchers began by creating ABEmax variants that replaced the SpCas9 nickase component with two engineered SpCas9 variants with altered PAM specificities: VRQR-SpCas9 targeting the NGA PAM sequence and VRER-SpCas9 targeting the NGCG PAM sequence. They named these editors VRQR-ABEmax and VRER-ABEmax. They then evaluated the base-editing activity of these ABE variants at six endogenous human genomic loci for each PAM in human HEK293T cells and found that although editing with ABEmax across six endogenous NGA PAM-containing sites resulted in low editing efficiency, editing with VRQR-ABEmax resulted in a 3.2-fold average improvement across all six sites.

They then tested the editing efficiency of ABEmax at six endogenous genomic sites in HEK293T cells containing NGCG PAMs and again observed minimal activity. In contrast, editing with VRER-ABEmax at those sites resulted in a sevenfold improvement over ABEmax.

Further experiments showed that the VRQR-, VRER- and SpCas9-NG variants were compatible with the ABEmax architecture and retained base-editing activity at sites containing their cognate nonNGG PAMs.

To expand the targeting scope of ABE even further, the researchers tried to examine whether Staphylococcus aureus Cas9 (SaCas9) could also be compatible with the ABEmax architecture. SaCas9 naturally targets NNGRRT PAMs, and an evolved variant called SaKKH recognizes NNNRRT PAMs.

The team generated both SaCas9 and SaKKH-ABEmax variants and tested them on six endogenous NNGRRT PAM sites and six endogenous NNHRRT PAM sites in HEK293T cells. They observed moderate editing efficiencies for SaABEmax and SaKKHABEmax, which contrasted with the high activities of SaCas9-derived CBEs that generally edit more efficiently than the corresponding SpCas9 CBE.

"These results suggest that further engineering or evolution may benefit targeting ABE with SaCas9 derivatives," the authors noted.

Given the potential utility of base editors with shifted or expanded activity windows, the researchers next sought to engineer base editor architectures that enabled editing at different protospacer positions. They hypothesized that circularly permuted Cas9 variants might result in expanded or otherwise altered activity windows, and chose five SpCas9 circular permutants — CP1012, CP1028, CP1041, CP1249, and CP1300 — based on both retention of DNA binding activity and predicted proximity to the single-strand DNA loop. They generated five CP-CBEmax and five CP-ABEmax variants and transfected them into HEK293T cells to test their base-editing activity at five endogenous genomic sites containing adenines and cytosines throughout the target 20-nucleotide protospacer.

The researchers found that four of the five CP-CBE variants were capable of base editing at all five sites without substantial indel formation, while CP1300-CBEmax demonstrated highly site-dependent base-editing activity. Three of the top four CP-CBEmax variants exhibited efficient editing activity, and CP1012-CBEmax and CP1028-CBEmax in particular showed broadening of the editing window from the canonical positions four to eight to positions four to 11 of the protospacer.

Similarly, most of the CP-ABEmax variants also exhibited a broadening of the editing window, the researchers said. CP-ABEmax variants retained efficient editing activity similar to that of ABEmax, and both ABEmax and the CP variants generated minimal indels.

Significantly, the researchers found that the window-broadening effect of the CP-ABEmax variants was pronounced, generally resulting in an expansion from the canonical window of protospacer positions four to seven for ABEmax to a window spanning positions four to 12.

When they measured the off-target base-editing efficiency of the CP base editors, the researchers found that it was similar to or less than that of CBEmax or ABEmax for C or A nucleotides within the canonical editing window. For C or A nucleotides outside of the canonical editing window, the expanded editing windows of the CP base editors resulted in higher off-target editing than CBEmax or ABEmax, in some cases.

"Together, these results demonstrate that circularly permuting the Cas9 nickase domain of base editors results in CBEmax and ABEmax variants with broadened or shifted editing windows," the authors concluded.

Share this post


Link to post
Share on other sites
JHenry

CRISPR hope for vax-resistant disease treatment


Gene-spliced antibodies show promise in mouse trials. Paul Biegler reports.


190516_CRISPR_Vax_full.jpg?ixlib=rails-2

Gene-editing technology could find solutions where vaccine fail.

VICTOR HABBICK VISIONS/SCIENCE PHOTO LIBRARY

Scientists have used the gene-splicing technology CRISPR to make virus-busting antibodies for a range of diseases that cannot, to date, be prevented with vaccines.

The researchers, led by Justin Taylor of the Fred Hutchinson Cancer Research Centre in Seattle, US, say the technique could mean new ways to tackle infections including HIV, influenza and Epstein Barr Virus (EBV), which causes glandular fever.

The team used CRISPR to alter the genetic code of human B-cells, coaxing them to make antibodies against those viruses and another wily agent called Respiratory Syncytial Virus or RSV.

RSV is harmless in healthy people but can be deadly for the very young and old. It causes lung disease that, in the US, puts more than 50,000 kids under five in hospital and kills 14,000 adults over 65 every year.

To see if the rejigged B-cells would actually fight off RSV, Taylor’s team put CRISPR-modified mouse B-cells into healthy mice. The critters were then subjected to a largish dose of RSV up the nostrils. Five days later the researchers took lung samples to see if the virus had taken up residence. RSV was nearly undetectable.

It’s an approach that addresses two problems with the current mainstay in stopping infection before it starts: vaccination. 

Vaccines challenge the body with a small dose of disease to spike immune cells into action. The cells can then be on war footing should the real illness come knocking down the track, helping them beat down the invader. 

But vaccines for some illnesses have been devilishly difficult to make.

The first RSV vaccine trial in 1966 left many infants and toddlers with a severe form of the disease, ultimately killing two. A second trial in 2016 was ineffective. 

HIV is another battlefront, with attempts to make a vaccine underway since the late 1980s.

“Our approach could be used to protect people against infections when a vaccine is not an option,” says Taylor. 

“HIV is a great example of an infection in which a protective vaccine doesn’t exist.”

There is also a whole bunch of people for whom getting vaccinated is out of the question.

These include the sick, elderly and people getting cancer chemotherapy, whose immune system may be so weakened that a vax would simply overwhelm them. Vaccines are a particular threat for people whose immunity has been wiped out in preparation for a bone marrow transplant.

The team’s research therefore included a study that put engineered B-cells into mice that lacked immune cells altogether, mimicking extreme immunodeficiency. After 82 days the cells were still making enough antibody to protect the mice from RSV infection.

It’s a finding that could, ultimately, shift the odds for bone marrow transplant recipients.

“These people are susceptible to a wide variety of viral, bacterial and fungal infections that we could use this technique to protect against while their immune systems recover,” explains Taylor.

The research is published in the journal Science Immunology.

 
SHARE TOTOGGLE DROPDOWN
Contribs paulbiegler 2.jpg?ixlib=rails 2.1
PAUL BIEGLER is a philosopher, physician and Adjunct Research Fellow in Bioethics at Monash University. He received the 2012 Australasian Association of Philosophy Media Prize and his book The Ethical Treatment of Depression (MIT Press 2011) won the Australian Museum Eureka Prize for Research in Ethics. 
FOLLOW
 
 

 

Share this post


Link to post
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Sign in to follow this  



  • Donate

    If Honeycomb has helped you, please help us by making a donation so we can provide you with even better features and services.

  • The Hive is Thriving!

    • Total Topics
      70,414
    • Total Posts
      476,193
  • 0_unsure-if-it-is-herpes.png

    Nervous about dating with herpes? Skip "the talk" and browse profiles here.

  • Posts

    • WilsoInAus
      @MikeHerp what? That’s the article you put up in response? Thats fraudulent and we all demand an apology. You cannot go around saying that half of people with HIV have it because they have HSV? Jesus Lord man, you need to pull it together, I thought you actually had some evidence. But no you’ve just got paranoia. You simply like to use fear to spread your message. Also HSV is not the major cofactor in HIV infections. Chlamydia and Gonorrhea are much, much stronger cofactors than HSV, multiple times so. But why let these simple facts get in the way of a bit of propaganda! Maybe we should all direct our funds to eliminating chlamydia according to your logic?!? Also you have not corrected your posts around FHC and viral research. Please do it quickly before you destroy any credibility in the article if it hadn’t already.
    • WilsoInAus
      Yes it is, did you actually read the thread and their other posts? Regardless this is a real life test.  The OP is ready to commit suicide if he has herpes impacting his anus. Based on negative swabs, negative PCR tests and the fact that herpes may not even be able to cause theses symptoms - are you prepared to make the call that he has genital herpes and it is causing the symptoms? Or is there room to doubt? Time to man up.
    • WilsoInAus
      And he eventually realised that his HSV-1 was oral and the redness from another cause went away. It is doubtful that anyone’s redness in that article was due to herpes, even those who have actually tested positive. This is a great lesson for @DJwah as you can see people get obsessed over herpes except those who actually have it.  That leads to the Henry Ford saying. Whether you think you have herpes, or whether you think you don’t, you’re right!
    • blurneworder
      @DJwah, here is a forum where someone says they have redness in the glans and they are also HSV1 positive  https://patient.info/forums/discuss/herpes-2-igg-test-3-1-569144
    • ayekayelle
      I’m on 1g daily and get OB’s still as well. I don’t understand  
×
×
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.